The BWEL trial showed significant weight loss in the WLI group, suggesting potential benefits in reducing cancer recurrence and mortality. The trial involved 3180 women with stage II/III HER2-negative ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results